Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America
$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones Leverages Vericel’s Commercial Capabilities and Presence in U.S. Burn Care Market Biologics License Application (BLA) Filing Planned for Fourth Quarter of 2019 Company to Host a Conference Call Today at 8:00 am
View HTML
Toggle Summary MediWound Files Annual Report on Form 20-F for the Year Ended December 31, 2018
YAVNE, Israel , March 26, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has filed its annual report on Form 20-F for the fiscal
View HTML
Toggle Summary MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid ® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued up to $43 Million for the Development of NexoBrid for Sulfur Mustard Injuries Conference call begins today at 8:30 a.m.
View HTML
Toggle Summary MediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time
YAVNE, Israel , March 18, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth
View HTML
Toggle Summary MediWound Announces Executive Leadership Changes
Chief Executive Officer Gal Cohen stepping down  Available for transition and ongoing strategic process support  Chief Financial & Operations Officer Sharon Malka will be appointed CEO   Chairmen of the Board Stephen T. Wills will serve as Active Chairman YAVNE, Israel , March 12, 2019 (GLOBE
View HTML
Toggle Summary MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns
Met Primary and All Secondary Endpoints with Statistically Significant Results Compared with Control Group Conference call with MediWound management and U.S. key opinion leader begins today, January 22, 2019 at 10:00 a.m. Eastern time YAVNE, Israel , Jan. 22, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd.
View HTML
Toggle Summary MediWound Reports Third Quarter 2018 Financial Results
Awarded additional BARDA contract valued up to $43 Million for the development of NexoBrid ® for sulfur mustard injuries Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel , Nov. 13, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical
View HTML
Toggle Summary MediWound to Host Third Quarter 2018 Financial Results Conference Call on November 13 at 8:30 a.m. Eastern Time
YAVNE, Israel , Nov. 07, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third
View HTML
Toggle Summary MediWound Awarded Additional BARDA Contract Valued Up to $43 Million for Development of NexoBrid® for Sulfur Mustard Injuries
YAVNE, Israel , Sept. 24, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Biomedical Advanced Research and Development
View HTML
Toggle Summary NexoBrid® Receives Marketing Authorization from Russia's Ministry of Health
Commercial launch is expected in the first half of 2019 YAVNE, Israel , Sept. 05, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced receipt
View HTML